A Prospective Study to Collect High-Quality Documentation of Bleeds, Health-Related Quality of Life (HRQoL), and Safety Outcomes in Patients With Hemophilia A Treated With Standard-of-Care Treatment

Inclusion Criteria:

- Cohort A: Patients greater than or equal to (>/=) 12 years of age at time of informed
consent

- Cohort A: Diagnosis of congenital hemophilia A of any severity and documented history
of high-titer inhibitor (that is, >/= 5 Bethesda units [BU])

- Cohort B: Pediatric patients less than (<) 12 years of age

- Cohort B: Diagnosis of congenital hemophilia A of any severity and documented history
of high-titer inhibitor (that is, >/=5 BU)

- Cohort C: Patients >/=12 years of age

- Cohort C: Diagnosis of congenital hemophilia A and FVIII activity <1 percent (%)

- Cohort C: No prior history of a positive inhibitor against FVIII

Exclusion Criteria:

- Prior RO5534262 (not applicable if patient agrees that prior RO5534262 will preclude
participation in a future investigational RO5534262 study)

- Bleeding disorder other than congenital hemophilia A

- Ongoing (or planned during the study) immune tolerance induction therapy with FVIII
or FVIII prophylaxis if currently/previously exposed to an inhibitor

- Previous or concomitant thromboembolic disease

- Known human immunodeficiency virus (HIV) infection with cluster of differentiation
(CD) 4 count <200 cells per microliter (cells/mcL)